DongKook Pharmaceutical Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	894,935	812,166	730,994	661,647	594,193	559,103
Other Revenue	-	-	-	-0	-	-
Revenue	894,935	812,166	730,994	661,647	594,193	559,103
Revenue Growth (YoY)	13.41%	11.10%	10.48%	11.35%	6.28%	15.93%
Cost of Revenue	412,818	364,598	320,443	281,999	244,272	221,983
Gross Profit	482,117	447,568	410,551	379,648	349,921	337,120
Selling, General & Admin	348,215	328,148	310,542	277,684	257,570	227,646
Research & Development	31,482	30,325	25,456	21,818	24,691	18,859
Amortization of Goodwill & Intangibles	1,538	771.45	124.19	92.39	114.47	114.41
Other Operating Expenses	1,590	1,343	1,278	1,350	887.7	732.4
Operating Expenses	392,525	367,703	343,677	306,107	286,702	254,518
Operating Income	89,592	79,865	66,873	73,541	63,219	82,602
Interest Expense	-2,371	-4,497	-5,868	-4,320	-2,883	-1,796
Interest & Investment Income	5,482	6,335	5,258	2,903	2,454	2,709
Earnings From Equity Investments	-1,495	2,553	-896.71	1,122	1,031	451.62
Currency Exchange Gain (Loss)	293.81	1,840	-65.38	708.54	2,657	-2,980
Other Non Operating Income (Expenses)	-3,339	-6,790	596.82	-603.97	932.71	-2,834
EBT Excluding Unusual Items	88,163	79,305	65,898	73,350	67,411	78,152
Gain (Loss) on Sale of Investments	-2,632	3,284	-5,814	-5,337	1,376	1,881
Gain (Loss) on Sale of Assets	5,640	2,148	752.89	618.82	966.3	-2.32
Asset Writedown	-881.71	-	-	-	-	-
Pretax Income	90,290	84,738	60,838	68,632	69,754	80,031
Income Tax Expense	23,665	22,401	11,966	13,876	16,837	22,150
Earnings From Continuing Operations	66,625	62,336	48,871	54,757	52,916	57,880
Minority Interest in Earnings	-5,825	-1,117	-1,696	-1,861	-2,571	-1,955
Net Income	60,800	61,219	47,175	52,896	50,345	55,925
Preferred Dividends & Other Adjustments	302.15	449.93	399.85	-	-	-
Net Income to Common	60,497	60,769	46,775	52,896	50,345	55,925
Net Income Growth	-1.39%	29.77%	-10.81%	5.07%	-9.98%	-0.69%
Shares Outstanding (Basic)	44	44	44	44	44	44
Shares Outstanding (Diluted)	45	45	45	45	45	45
Shares Change (YoY)	0.01%	0.01%	0.02%	0.01%	-	-
EPS (Basic)	1368.58	1382.16	1064.03	1203.46	1145.56	1272.52
EPS (Diluted)	1358.99	1368.41	1054.64	1183.00	1126.00	1251.00
EPS Growth	-1.39%	29.75%	-10.85%	5.06%	-9.99%	-0.64%
Free Cash Flow	41,534	48,800	7,616	-7,005	-6,352	19,502
Free Cash Flow Per Share	928.37	1090.81	170.27	-156.64	-142.04	436.09
Dividend Per Share	200.000	200.000	-	-	-	-
Gross Margin	53.87%	55.11%	56.16%	57.38%	58.89%	60.30%
Operating Margin	10.01%	9.83%	9.15%	11.12%	10.64%	14.77%
Profit Margin	6.76%	7.48%	6.40%	7.99%	8.47%	10.00%
Free Cash Flow Margin	4.64%	6.01%	1.04%	-1.06%	-1.07%	3.49%
EBITDA	120,807	108,327	87,971	92,728	80,577	97,714
EBITDA Margin	13.50%	13.34%	12.03%	14.02%	13.56%	17.48%
D&A For EBITDA	31,215	28,462	21,098	19,187	17,358	15,112
EBIT	89,592	79,865	66,873	73,541	63,219	82,602
EBIT Margin	10.01%	9.83%	9.15%	11.12%	10.64%	14.77%
Effective Tax Rate	26.21%	26.44%	19.67%	20.22%	24.14%	27.68%
Advertising Expenses	-	83,743	76,804	66,472	67,064	58,171

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.